Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention

计划入组 176 人 · 首次发布于 2024 年 2 月 23 日

Clinical Outcomes of Contemporary IMPELLA Devices in Cardiogenic Shock and High-risk Percutaneous Coronary Intervention

计划入组 700 人 · 首次发布于 2024 年 11 月 15 日

Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

计划入组 358 人 · 首次发布于 2025 年 12 月 22 日

Cangrelor(Kengreal, Kengrexal)

C₁₇H₂₅Cl₂F₃N₅O₁₂P₃S₂

Abciximab

Bivalirudin(Angiomax)

C₉₈H₁₃₈N₂₄O₃₃ · Rx

EFFECTIVE INTERVENTION

Gambia The

ADVANTAGE RISK MANAGEMENT CO., LTD.

Japan

HIGH POINT UNIVERSITY

United States

Supira Medical Raises $120M in Series E Funding, Completes SUPPORT I Enrollment for Novel Cardiac Support Device

Supira Medical Receives FDA Approval for SUPPORT II Pivotal Trial of Next-Generation Percutaneous Ventricular Assist Device

Impella ECP Heart Pump Demonstrates Safety and Efficacy in High-Risk PCI Patients